drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, gene-modified chimeric antigen receptor (CAR) T cells produced with a non-viral vector, engineered to target mesothelin and MUC1 on tumor cells and to auto-secrete multifunctional antibodies to enhance antitumor immunity within the tumor microenvironment; evaluated in a dose-escalation regimen (5×10^5, 1×10^6, 5×10^6 cells/kg).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a non-viral vector to express chimeric antigen receptors recognizing mesothelin and MUC1 on tumor cells, triggering CAR-mediated T-cell activation and cytolytic killing via CD3ζ and costimulatory signaling; additionally engineered to secrete multifunctional antibodies within the tumor microenvironment to enhance antitumor immunity (e.g., overcoming immunosuppression/checkpoints) and amplify T-cell activity.
drug_name
Fast CAR T cells
nct_id_drug_ref
NCT06327997